MMJ BioPharma Cultivation

MMJ BioPharma Cultivation is a specialized biotechnology firm dedicated to the development of cannabis-based prescription medicines for chronic and debilitating diseases. As a subsidiary of MMJ International Holdings, the company holds a rare DEA Schedule 1 manufacturing license, allowing it to cultivate and extract pharmaceutical-grade cannabinoids in its Rhode Island facility. Their lead clinical programs, MMJ-001 and MMJ-002, target Multiple Sclerosis and Huntington's Disease, respectively, and have advanced into Phase 2 clinical trials. The company focuses on meeting rigorous FDA standards for botanical drug development to ensure consistency and efficacy. By bridging the gap between traditional herbal cannabis and modern pharmacology, MMJ BioPharma Cultivation aims to provide evidence-based therapies for patients with limited treatment options.